<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39116863</PMID><DateCompleted><Year>2024</Year><Month>08</Month><Day>08</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0016-3813</ISSN><JournalIssue CitedMedium="Internet"><Volume>160</Volume><Issue>2</Issue><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Gaceta medica de Mexico</Title><ISOAbbreviation>Gac Med Mex</ISOAbbreviation></Journal><ArticleTitle>Clinical-epidemiological characterization of patients with long COVID in Mexico.</ArticleTitle><Pagination><StartPage>136</StartPage><EndPage>143</EndPage><MedlinePgn>136-143</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.24875/GMM.M24000875</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Long COVID is defined as the persistence of COVID-19 symptoms four weeks after having undergone acute infection, according to the most recent CDC definition. It is estimated that there are 65 million people affected by this entity, although other figures speak of 200 million.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To characterize the population affected by long COVID in Mexico.</AbstractText><AbstractText Label="MATERIAL AND METHODS" NlmCategory="METHODS">Patients older than 18 years who agreed to answer an online survey and who met the criteria for long COVID were included.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Data from 203 subjects were included, with 138 (68.0%) being found to be females, and average age to be 41.8 years; 29.6% had severe disease, and 70.4%, mild to moderate disease; 89.7% had received prior COVID-19 vaccination: 6.9% had received one dose; 31.5%, two doses; and 51.2%, three or more doses. The main risk factors were diabetes, overweight or obesity, and hypertension. The most commonly reported symptom was fatigue, followed by other neuropsychiatric manifestations.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">It is important for the population affected by long COVID to be characterized in order to generate diagnostic and treatment protocols.</AbstractText><CopyrightInformation>Copyright: &#xa9; 2024 Permanyer.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Carpio-Orantes</LastName><ForeName>Luis Del</ForeName><Initials>LD</Initials><AffiliationInfo><Affiliation>Grupo de Estudio para el Diagn&#xf3;stico y Tratamiento de COVID-19 en Veracruz, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trelles-Hern&#xe1;ndez</LastName><ForeName>Daniela</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Grupo de Estudio para el Diagn&#xf3;stico y Tratamiento de COVID-19 en Veracruz, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garc&#xed;a-M&#xe9;ndez</LastName><ForeName>Sergio</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Grupo de Estudio para el Diagn&#xf3;stico y Tratamiento de COVID-19 en Veracruz, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>S&#xe1;nchez-D&#xed;az</LastName><ForeName>Jes&#xfa;s S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Grupo de Estudio para el Diagn&#xf3;stico y Tratamiento de COVID-19 en Veracruz, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aguilar-Silva</LastName><ForeName>Andr&#xe9;s</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Grupo de Estudio para el Diagn&#xf3;stico y Tratamiento de COVID-19 en Veracruz, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>L&#xf3;pez-Vargas</LastName><ForeName>Ener R</ForeName><Initials>ER</Initials><AffiliationInfo><Affiliation>Grupo de Estudio para el Diagn&#xf3;stico y Tratamiento de COVID-19 en Veracruz, M&#xe9;xico.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Caracterizaci&#xf3;n cl&#xed;nico-epidemiol&#xf3;gica de los pacientes con COVID persistente en M&#xe9;xico.</VernacularTitle></Article><MedlineJournalInfo><Country>Mexico</Country><MedlineTA>Gac Med Mex</MedlineTA><NlmUniqueID>0010333</NlmUniqueID><ISSNLinking>0016-3813</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008800" MajorTopicYN="N" Type="Geographic">Mexico</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009765" MajorTopicYN="N">Obesity</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="spa"><AbstractText Label="ANTECEDENTES" NlmCategory="BACKGROUND">El COVID persistente se define como la persistencia de s&#xed;ntomas de COVID-19 despu&#xe9;s de cuatro semanas de cursar con un cuadro agudo, seg&#xfa;n la definici&#xf3;n m&#xe1;s reciente de los Centers for Disease Control and Prevention. Se estima que existen 65 millones de personas afectadas por esta entidad, aunque algunos reportes indican 200 millones.</AbstractText><AbstractText Label="OBJETIVO" NlmCategory="OBJECTIVE">Caracterizar a la poblaci&#xf3;n afectada por COVID persistente en M&#xe9;xico.</AbstractText><AbstractText Label="MATERIAL Y M&#xc9;TODOS" NlmCategory="UNASSIGNED">Se incluyeron pacientes mayores de 18 a&#xf1;os que consintieron responder a una encuesta en l&#xed;nea y que cumpl&#xed;an los criterios de COVID persistente.</AbstractText><AbstractText Label="RESULTADOS" NlmCategory="RESULTS">Se incluyeron los datos de 203 sujetos. Se identific&#xf3; que 138 (68.0 %) contestaron ser del sexo femenino, con una media de edad de 41.8 a&#xf1;os; 29.6 % present&#xf3; enfermedad grave y 70.4 %, enfermedad leve a moderada; 89.7 % hab&#xed;a recibido vacunas previas para COVID-19: 6.9 %, una dosis; 31.5 %, dos dosis; y 51.2 %, tres o m&#xe1;s dosis. Los principales factores de riesgo fueron diabetes, sobrepeso u obesidad e hipertensi&#xf3;n arterial sist&#xe9;mica. El principal s&#xed;ntoma reportado fue fatiga, seguido de otras manifestaciones neuropsiqui&#xe1;tricas.</AbstractText><AbstractText Label="CONCLUSI&#xd3;N" NlmCategory="UNASSIGNED">Es importante caracterizar a la poblaci&#xf3;n para generar protocolos de diagn&#xf3;stico y tratamiento.</AbstractText><CopyrightInformation>Copyright: &#xa9; 2024 Permanyer.</CopyrightInformation></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID persistente</Keyword><Keyword MajorTopicYN="N">Disautonom&#xed;as</Keyword><Keyword MajorTopicYN="N">Dysautonomia</Keyword><Keyword MajorTopicYN="N">Fatiga</Keyword><Keyword MajorTopicYN="N">Fatigue</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>8</Month><Day>9</Day><Hour>0</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>8</Month><Day>9</Day><Hour>0</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>8</Month><Day>8</Day><Hour>18</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39116863</ArticleId><ArticleId IdType="doi">10.24875/GMM.M24000875</ArticleId><ArticleId IdType="pii">j160/2/136</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>